Physician profile
Christopher Ryan Easterling
NPI 1538554134
$4,111.39
in general payments reported to CMS, 2019-2025
35 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $232 · 2021: $124 · 2022: $534 · 2023: $844 · 2024: $1,108 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $475.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $426.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $395.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $362.09 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $299.28 | 2020-2025 | |
| Amgen INC. | $295.08 | 2019-2025 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $290.01 | 2023-2025 | Veozah, Myrbetriq, Vesicare |
| Glaxosmithkline, LLC. | $276.34 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $247.96 | 2022-2025 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.30 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $97.86 | 2022-2023 | |
| Exact Sciences Corporation | $84.90 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $59.47 | 2022-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $55.84 | 2019-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $50.59 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $49.70 | 2025 | Voquezna |
| Mylan Specialty L.P. | $46.77 | 2019-2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $46.15 | 2023 | Quviviq |
| Allergan, INC. | $35.37 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $31.29 | 2022-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $29.47 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.39 | 2023-2024 | Rexulti |
| Abbott Laboratories | $27.30 | 2023-2025 | Freestyle Libre |
| Lundbeck LLC | $24.82 | 2025 | Vyepti |
| Xeris Pharmaceuticals, INC. | $24.08 | 2024 | Recorlev |
| Hologic Sales and Service, LLC | $22.23 | 2025 | Aptima |
| Genentech USA, INC. | $21.18 | 2020 | |
| Corium, LLC | $20.10 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.32 | 2024 | Nuzyra |
| Sumitomo Pharma America, INC. | $17.22 | 2024 | Gemtesa |
| Inspire Medical Systems, INC. | $16.70 | 2025 | Inspire |
| Celgene Corporation | $14.76 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2024 | Xifaxan |
| Pacira Therapeutics, INC. | $11.43 | 2019 | |
| Amarin Pharma, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Easterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.